ArticleBlood cell therapy2025

The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.

Takashi Shimakawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.